Back

Estimated plasma volume in heart failure with reduced ejection fraction: ACE inhibitors versus angiotensin receptor/neprilysin inhibitor in follow up

31 August 2024 (09:00 - 09:40)
Organised by: Logo
Congress Presentation Part of: Angiotensin and angiotensin receptor neprilysin inhibitors in heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Sara Varga

General Hospital Dr. Ivo Pedisic, Sisak (Croatia)

7 More presentations in this session

Presentation thumbnail
Guideline-directed medical therapy patterns in heart failure with reduced ejection fraction: the OPTIMA-HF registry
Doctor S. Paolillo (Naples, IT)
Abstract Slides
Presentation thumbnail
Quality of life in patients with heart failure and improved ejection fraction: one-year follow-up with ARNI and SGLT2i
Professor S. Tadic (Novi Sad, RS)
Abstract Slides
Presentation thumbnail
Real world evidence of Sacubitril/Valsartan in octogenarian patients with heart failure. Results From the PARACHUTE-HF Study
Doctor N. Okuda (Kawagoe, JP)
Abstract Slides
Presentation thumbnail
Safety and efficacy of initiation SGLT in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease on top of standard therapy with ARNI or ACE-i
Mrs O. Obertynska (Vinnitsa, UA)
Abstract Slides
Presentation thumbnail
Association of renal circulation at acute phase with decongestion level at discharge in patients admitted for acute decompensated heart failure
Doctor K. Kayama (Nagoya, JP)
Abstract Slides

Access the full session

Session thumbnail
Angiotensin and angiotensin receptor neprilysin inhibitors in heart failure

The Event

Event poster

ESC Congress 2024

31 August 2024 09:00 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023
thumbnail
Congress Session
Navigating through heart failure device therapies

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources